Skip to main content

Are Anti-Angiogenic Drugs Useful in Neurodegenerative Disorders?

Buy Article:

$63.00 plus tax (Refund Policy)


Recently, a pivotal role for neuroinflammation in the pathogenesis of several neurodegenerative diseases has been recognized. Once activated, glial cells produce pathological amounts of neurotoxic substances driving neurodegeneration into chronic progression through a self-propagating cycle. Nevertheless, mounting evidence suggests that also angiogenesis may importantly contribute to neurodegeneration, since activated glial cells may release also pro-angiogenic factors. A deregulation of the balance between pro- and anti-angiogenic mediators has been reported in in vivo and in vitro models of neuroinflammation. Indeed, in Alzheimer's disease brain, a significant increase in the expression of pro-angiogenic growth factors, such as Vvascular endothelial growth factor, was found strictly co-localized with senile plaques. In addition, converging results indicate that thalidomide and its derivatives, having newly discovered anti-inflammatory and anti-angiogenic properties, are useful in the prevention of several hallmarks of neurodegeneration occurring in experimental models of Parkinson's and Alzheimer's diseases. The present review primarily discusses about the possible roles, still under debate, of angiogenesis in neurodegeneration, and focuses on the identification of new possible anti-angiogenic compounds that could open new horizons in the treatment of neurodegenerative diseases where angiogenesis is detrimental.

Keywords: Alzheimer's disease; Angiogenesis; Anti-Angiogenic Therapy; Bevacizumab; FITC-albumin; Huntington's disease; MMPs; Microglia; PEA; Pegaptanib; Ranibizumab; S1P; Sphingosine-1-phosphate; TIMPs; TNF; VEGF; aetiopathogenesis; angiogenesis; angiopathy; blood-brain barrier; central nervous system; embryonic neuroectoderm; encephalomyelitis; gliosis; hippocampus; hypoxia; ischemia; lactobionamide; lactobionolactone; maculophathy; metalloproteinases; multiple sclerosis; neurodegeneration; palmitoylethanolamide; prostaglandins; retina; vascular endothelial frowth factor; vasculogenesis; vasodilation

Document Type: Research Article


Publication date: December 1, 2010

More about this publication?
  • CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in neurological and CNS disorders. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Partial Open Access Content
Partial Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more